RxDoctor Payments Data

Melissa Ambrosio, PA

Physician Assistant · Ventura, CANPI 1871837872

Payments from drug & device makers

$2,657in general payments, 2019–2025

Across 91 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$674
  • AbbVie$499
  • Regeneron Healthcare Solutions, Inc.$297
  • Edwards Lifesciences$158
  • LEO Pharma Inc.$152
  • Davol Inc.$149
  • plus $728 from 11 others

What the payments were for

  • Consulting fees$40615%
  • Food & beverage$2,02176%
  • Education$2309%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,657 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$7,411
Medicare patients
31
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa13$250,175
OtezlaApremilast17$85,799
Dupixent PenDupilumab24$82,185
Humira(Cf) PenAdalimumab11$73,286
Clobetasol Propionate16$1,643
Fluorouracil11$823
Triamcinolone Acetonide50$687
Ketoconazole36$602
Fluocinonide19$409
Doxycycline Hyclate11$229
Hydrocortisone18$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$79$85,79917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →